{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:27:29Z","timestamp":1792099649188,"version":"4.4.0"},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T00:00:00Z","timestamp":1484611200000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"name":"Shire Human Genetic Therapies, Inc"},{"name":"Shire International GmbH"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1111\/ijcp.12914","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T20:10:35Z","timestamp":1484683835000},"page":"e12914","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Time delays in the diagnosis and treatment of Fabry disease"],"prefix":"10.1155","volume":"71","author":[{"given":"Ricardo","family":"Reisin","sequence":"first","affiliation":[{"name":"Hospital Brit\u00e1nico de Buenos Aires; Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Perrin","sequence":"additional","affiliation":[{"name":"Shire; Zug Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garc\u00eda-Pav\u00eda","sequence":"additional","affiliation":[{"name":"Heart Failure and Inherited Cardiac Diseases Unit; Department of Cardiology; Hospital Universitario Puerta de Hierro Majadahonda; Madrid Spain"},{"name":"Francisco de Vitoria University; Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,17]]},"reference":[{"key":"10.1111\/ijcp.12914-BIB0001|ijcp12914-cit-0001","first-page":"3733","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Desnick","year":"2001"},{"key":"10.1111\/ijcp.12914-BIB0002|ijcp12914-cit-0002","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08035250500275022","article-title":"Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr"},{"key":"10.1111\/ijcp.12914-BIB0003|ijcp12914-cit-0003","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1111\/ijcp.12914-BIB0004|ijcp12914-cit-0004","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1111\/ijcp.12914-BIB0005|ijcp12914-cit-0005","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1012993305223","article-title":"Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes","volume":"24","author":"Whybra","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/ijcp.12914-BIB0006|ijcp12914-cit-0006","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1111\/ijcp.12914-BIB0007|ijcp12914-cit-0007","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12914-BIB0008|ijcp12914-cit-0008","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/ijcp.12914-BIB0009|ijcp12914-cit-0009","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/ijcp.12914-BIB0010|ijcp12914-cit-0010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","article-title":"Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment","volume":"10","author":"Kampmann","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1111\/ijcp.12914-BIB0011|ijcp12914-cit-0011","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1111\/ijcp.12914-BIB0012|ijcp12914-cit-0012","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000369293","article-title":"Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease","volume":"38","author":"Fellgiebel","year":"2014","journal-title":"Cerebrovasc Dis"},{"key":"10.1111\/ijcp.12914-BIB0013|ijcp12914-cit-0013","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1517\/17530059.2013.846322","article-title":"Difficulties and barriers in diagnosing Fabry disease: what can be learnt from the literature?","volume":"7","author":"Thomas","year":"2013","journal-title":"Expert Opin Med Diagn"},{"key":"10.1111\/ijcp.12914-BIB0014|ijcp12914-cit-0014","volume-title":"Fabry Disease: Perspectives from 5 Years of FOS","author":"Beck","year":"2006"},{"key":"10.1111\/ijcp.12914-BIB0015|ijcp12914-cit-0015","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/ijcp.12914-BIB0016|ijcp12914-cit-0016","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10897-007-9128-x","article-title":"Diagnosis of Fabry disease via analysis of family history","volume":"17","author":"Laney","year":"2008","journal-title":"J Genet Couns"},{"key":"10.1111\/ijcp.12914-BIB0017|ijcp12914-cit-0017","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12914-BIB0018|ijcp12914-cit-0018","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int"},{"key":"10.1111\/ijcp.12914-BIB0019|ijcp12914-cit-0019","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","article-title":"Effects of enzyme replacement therapy in Fabry disease-a comprehensive review of the medical literature","volume":"12","author":"Lidove","year":"2010","journal-title":"Genet Med"},{"key":"10.1111\/ijcp.12914-BIB0020|ijcp12914-cit-0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/GIM.0b013e3181f6e676","article-title":"Therapeutic goals in the treatment of Fabry disease","volume":"12","author":"Mehta","year":"2010","journal-title":"Genet Med"},{"key":"10.1111\/ijcp.12914-BIB0021|ijcp12914-cit-0021","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin Genet"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12914","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ijcp.12914\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T01:10:01Z","timestamp":1643332201000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.12914","archive":["Portico"],"relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}